| アブストラクト | BACKGROUND: Resmetirom is the first approved liver-directed thyroid hormone receptor-beta agonist for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis. Early liver-event reporting may be distorted by indication leakage (the treated disease or its manifestations recorded as adverse events), disease progression, and surveillance bias. METHODS: We analyzed FDA Adverse Event Reporting System (FAERS) data from 2024Q1 through 2026Q1. Deduplicated primary- or secondary-suspect reports were assessed at preferred-term, system-organ-class, and nine predefined clinical-cluster levels using frequentist and Bayesian disproportionality metrics. References included all FAERS, US MASH-indication reports, and an exploratory 144-report active comparator. Sensitivity analyses examined cirrhosis indications, serious outcomes, onset-data selection, and co-medications. RESULTS: Among 3,155,054 deduplicated cases, 1,429 resmetirom reports were analyzed. Versus all non-resmetirom reports, RORs (95% CIs) were 12.13 (10.61-13.88) for hepatocellular injury and 11.46 (9.24-14.21) for cholestasis/biliary events. Gastrointestinal, thyroid/metabolic, and rash/hypersensitivity reporting was also enriched. Hepatic estimates remained elevated after excluding 35 cirrhosis-indication reports and in restricted comparisons, although sparse cells produced wide confidence intervals. The active comparator comprised 142 GLP-1/GIP and two pioglitazone reports. Against this reference, RORs were 1.36 (0.93-1.99) for gastrointestinal intolerance, 0.93 (0.59-1.47) for nausea, 1.42 (0.18-11.18) for cholelithiasis, and 1.95 (1.12-3.41) for diarrhoea. The first three attenuated, whereas diarrhoea remained elevated. Only 206 reports (14.4%) had valid exact onset dates, with systematic differences from reports lacking dates. Sex was missing in 94.6%. Gemfibrozil and clopidogrel were co-reported in three and 25 cases, respectively. CONCLUSION: Early FAERS reporting patterns recapitulated recognized gastrointestinal, hepatic, biliary, cutaneous, and thyroid/metabolic domains. Comparator-dependent attenuation suggests that crude all-FAERS estimates partly reflect treatment-context reporting. However, the small GLP-1/GIP-dominant comparator, missing data, target-organ confounding, and spontaneous-report limitations preclude incidence, comparative-risk, or causal inference. These hypothesis-generating patterns support clinical monitoring and denominator-based confirmation. |
| 組織名 | Department of General Surgery, Division of Biliary Tract Surgery, West China,;Hospital, Sichuan University, Chengdu, Sichuan, China.;Department of Ultrasonography, West China Hospital, Sichuan University, Chengdu,;China. |